The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 21, 2017

Filed:

Aug. 29, 2014
Applicant:

Longhorn Vaccines and Diagnostics, Llc, Bethesda, MD (US);

Inventors:

Gerald W. Fischer, Bethesda, MD (US);

Luke T. Daum, San Antonio, TX (US);

Clara Jebet Sei, Germantown, MD (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 39/04 (2006.01); C07K 16/12 (2006.01); A61K 39/40 (2006.01); C07K 14/35 (2006.01); G01N 33/50 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/04 (2013.01); A61K 39/12 (2013.01); A61K 39/40 (2013.01); C07K 14/35 (2013.01); C07K 16/1289 (2013.01); G01N 33/5055 (2013.01); A61K 2039/521 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6081 (2013.01); A61K 2039/70 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/31 (2013.01); C12N 2760/16134 (2013.01);
Abstract

The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.


Find Patent Forward Citations

Loading…